KOWA 303
-
StatusAccepting Candidates
-
Age18 Years - N/A
-
SexesAll
-
Healthy VolunteersNo
Objective
A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.
Details
Full study title | A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration with Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy |
Protocol number | OCR44063 |
ClinicalTrials.gov ID | NCT05826353 |
Phase | Phase 3 |
Eligibility
Inclusion Criteria:
Is at least 18 years old at the screening visit (Visit 1)
Has a diagnosis of FECD at Visit 1
Meet all other inclusion criteria outlined in the Clinical Study Protocol.
Exclusion Criteria:
Is a female subject of childbearing potential and any of the following is true:
is pregnant or lactating/breastfeeding, or
is not surgically sterile, not post-menopausal (no menses for the previous 12 months), or not practicing an effective method of birth control as determined by the Investigator (eg, oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or partner with vasectomy)
Meet any other exclusion criteria outlined in the Clinical Study Protocol.
Lead researcher
Participate in a study
Here are some general steps to consider when participating in a research study:
-
Step1
Contact the research team
Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.
Primary contact
-
Step2
Get screened to confirm eligibility
You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.
-
Step3
Provide your consent to participate
If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.
-
Step4
Participate
If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.